Obesity evidence dossier

Ecnoglutide

A China-approved weekly GLP-1RA with peer-reviewed Phase 3 obesity efficacy; IN-B00009 is the regional Korean-development identity rather than a distinct molecule.

Sciwind Biosciences; licensed to HK inno.N for Korean development and commercializationApproved in China for chronic weight management; HK inno.N’s Korean IN-B00009 obesity program is Phase 3 (NCT07192263), not yet recruiting.Subcutaneous injection, once weekly.

Weight loss score /10057

Comparison statusOther trial data · Includes treatment stops

EvidencePhase 3 · Journal article

Follow-up40 weeks

Total weight loss

13.2%

SLIMMER · 2.4 mg weekly · week 40 · Includes treatment stops

Placebo-adjusted

13.3%

Difference from placebo in the same study when reported.

Study context

Once-weekly cAMP-biased GLP-1 receptor agonist./Adults with obesity or overweight in China, without diabetes/664 participants across the study/40-week endpoint

Baseline: See the source for enrollment criteria

Ranked result & calculation

SLIMMER · 2.4 mg weekly · 40 weeks

Adults with obesity or overweight in China, without diabetes. 664 participants across the study (not this dose arm alone).

Includes treatment stops. Treatment-policy results estimate outcomes regardless of stopping treatment.

Average weight loss: 13.2%
Placebo group: 0.1% gain
Beyond placebo: 13.3 percentage points (published difference)
97% confidence interval, beyond placebo: 11.3–15.3 points
Stopped due to adverse events: Not verified for this result

Primary endpoint at week 40 in a 48-week study. Placebo gained 0.1%.

Score: 70% × 54.1 total-loss points + 30% × 64.5 beyond-placebo points = 57/100, rounded. Conversion scales

SLIMMER, Lancet Diabetes & Endocrinology ↗Phase 3 · Journal article · Reviewed 2026-09-21

Evidence

Benchmark read

SLIMMER: Includes treatment stops. Primary endpoint at week 40 in a 48-week study. Placebo gained 0.1%.

Safety

Side effects and cautions

Discontinuation read

Adverse-event discontinuation has not been verified for this result.

Common side effects

The Phase 3 publication reported a favorable safety profile. As with other GLP-1RAs, gastrointestinal tolerability remains the key practical safety domain.

Main cautions

China approval does not establish approval in Korea or the United States. Regional regulatory status and product labeling should be assessed separately.

Upcoming catalyst

What to watch next

Korean Phase 3 IN-B00009 obesity program.

Linked clinical trials

Trials in the saddl3 obesity snapshot

Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.

NCT05813795

Phase 3

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

Hangzhou Sciwind Biosciences Co., Ltd.

Non-diabetic obesity

Completed

Apr 30, 2025

NCT07281937

Phase 2

A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Verdiva Bio Dev Limited

Non-diabetic obesity

Active

Mar 18, 2026

NCT07243171

Phase 2

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Hangzhou Sciwind Biosciences Co., Ltd.

Non-diabetic obesity

Recruiting

Jan 28, 2026

NCT07073417

Phase 2

A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

Hangzhou Sciwind Biosciences Co., Ltd.

Non-diabetic obesity

Recruiting

Aug 20, 2025

NCT05111912